Skip to main content
VALIRX PLC logo

VALIRX PLC — Investor Relations & Filings

Ticker · VAL ISIN · GB00BLH13C52 LEI · 213800VQKB9SJCQDET40 IL Professional, scientific and technical activities
Open in API
Filings indexed 574 across all filing types
Latest filing 2019-05-23 Major Shareholding Noti…
Country GB United Kingdom
Listing IL VAL

About VALIRX PLC

https://www.valirx.com/

ValiRx PLC is a life science company that accelerates the development of therapeutics and diagnostics, with a primary focus on oncology and women's health. The company's business model centers on identifying and progressing promising early-stage scientific discoveries through pre-clinical and clinical development. ValiRx provides scientific, financial, and commercial expertise to translate novel research into clinically validated treatments, aiming to improve patient outcomes in its target therapeutic areas.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document text contains multiple sections titled "NOTIFICATION OF MAJOR HOLDINGS" and details changes in the percentage of voting rights held by a specific entity ("European High Growth Opportunities Securitization Fund"). It explicitly mentions the issuer (ValiRx plc), the date the threshold was crossed, and the resulting shareholding percentage (e.g., 9.17% and 7.94%). This structure is characteristic of regulatory filings reporting changes in significant share ownership, which corresponds to the Major Shareholding Notification category.
2019-05-23 English
Subscription Agreement Update
Share Issue/Capital Change Classification · 1% confidence The document begins with an 'RNS Number' and is clearly a regulatory announcement from 'ValiRx PLC' dated May 22, 2019. The content discusses an update on a 'Subscription Agreement' for shares (Tranche 2), details regarding 'Convertible Funds & Warrants', and potential 'Break Fee' implications, all related to financing and capital structure changes. While it touches upon financing (CAP), the primary nature of this document is a formal, immediate disclosure to the market via the RNS system, detailing updates on financial arrangements and share issuance timing. Since it is a general regulatory announcement that doesn't fit perfectly into specific categories like CAP (which is usually the definitive action) or SHA (which is usually the final share issue), and it is explicitly marked as an RNS release, the most appropriate general classification is Regulatory Filings (RNS). It is not a full report (10-K, IR) nor a simple dividend notice or earnings release.
2019-05-22 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1473 characters) and contains an 'RNS Number' and mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Price Monitoring Extension' for an auction call period, which is a specific, short-form regulatory market announcement rather than a comprehensive financial report (like 10-K or IR) or a standard corporate action (like DIV or CAP). Since it is a general regulatory announcement distributed via the RNS system that doesn't fit into the more specific categories (like DIRS, MANG, or DIV), the most appropriate classification is the general Regulatory Filings fallback category.
2019-05-13 English
Acquisition of Intellectual Property& JV Agreement
M&A Activity Classification · 1% confidence The document begins with an 'RNS Number' and the date '02 May 2019', indicating it is a regulatory news service announcement from the London Stock Exchange. The content details a significant corporate action: the acquisition of Intellectual Property (IP) assets and the signing of a Letter of Intent (LOI) for a Joint Venture. This type of announcement, which details corporate transactions, strategic agreements, and material business updates released via an official news service, fits best under the general 'Regulatory Filings' category (RNS) as it is not a specific financial report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). Although it contains elements of M&A (TAR), the primary function here is the immediate public disclosure via the RNS system.
2019-05-02 English
Second Price Monitoring Extn
Transaction in Own Shares Classification · 1% confidence The document contains an 'RNS Number' and explicitly states that the information is provided by 'RNS, the news service of the London Stock Exchange,' which is approved by the Financial Conduct Authority (FCA). The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific type of regulatory market announcement. Since this is a general regulatory announcement that doesn't fit the specific categories like DIV, ER, or 10-K, the most appropriate classification is the general regulatory filing category.
2019-04-29 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1475 characters) and contains the header 'RNS Number : 4366X'. It announces a 'Price Monitoring Extension' related to trading procedures on the London Stock Exchange. This is a general regulatory announcement that does not fit into specific financial reporting categories like 10-K, ER, or IR. Since it is a general regulatory notice provided via the RNS service, the most appropriate classification is Regulatory Filings (RNS), which serves as the fallback for miscellaneous regulatory announcements.
2019-04-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.